Treatment with a combination of ledipasvir and sofosbuvir can lead to large economic gains.
Mark L. Fuerst
Clinicians need to carefully plan treatment when prescribing DAA therapy for patients infected with hepatitis C virus who have hepatocellular carcinoma.
All hepatitis C virus genotypes respond to therapy
Recipients of hepatitis C-infected kidneys treated with direct-acting antiviral agents are disease-free one year post-transplant.
Females, Hispanics screened less often for highly curable infection.
More patients could take advantage of shorter direct-acting antiviral treatment duration.
With the advent of new direct-acting antiviral agents, HCV treatment has greatly improved, making identification of infected individuals even more imperative.
More effort needed to integrate screening with follow-up care to prevent spread of the virus.
Timely treatment with direct-acting antivirals is highly cost-effective in virtually all patients infected with HCV.
An innovative telemedicine model could substantially reduce the burden of chronic hepatitis C infection.